Collegium Pharmaceutical, Inc. Stock Split Ratio
Collegium Pharmaceutical, Inc. (COLL) reported Stock Split Ratio of 14.49% for the 1-month period ending 2015-04-30, per its 10-K filed 2018-03-07.
Discontinued › Notes › Equity › Stockholders' Equity Note
us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 · last filed 2018-03-07
- 2015-04-30: Stockholders' Equity Note, Stock Split, Conversion Ratio 1 month 14.49%; Stockholders' Equity Note, Stock Split, Conversion Ratio 1 month as first filed 14.49%.
| Period end | Stockholders' Equity Note, Stock Split, Conversion Ratio 1 month | Stockholders' Equity Note, Stock Split, Conversion Ratio 1 month as first filed |
|---|---|---|
| 2015-04-30 | 14.49% 10-K · filed 2018-03-07 | 14.49% 10-Q/A · filed 2015-07-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |